 Stealth BioTherapeutics NASDAQ:MITO had its price target cut by Nomura from 14.00 to 10.00 in a research report report published on Friday, The Fly reports. They currently have a buy rating on the stock. A number of other analysts also recently commented on MITO. Cantor Fitzgerald reiterated an overweight rating and set a 10.00 target ... 